pulmicort turbuhaler 200 mikrogramov/vdih prašek za inhaliranje
astrazeneca ab - budezonid - prašek za inhaliranje - budezonid 200 µg / 1 vdih - budezonid
ondexxya
astrazeneca ab - andexanet alfa - drog stranske učinke in neželene učinke - vsi drugi terapevtski izdelki - pri odraslih bolnikih z neposrednim faktorja xa (fxa) serotonina (apixaban ali rivaroxaban), ko odprave antikoagulacijo je potrebna zaradi smrtno nevarno ali nenadzorovana krvavitev.
faslodex
astrazeneca ab - fulvestrant - neoplazme dojke - endokrini terapije, anti-estrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - ali perimenopausal ženske, kombinacija zdravljenja z palbociclib je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.
evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
saphnelo
astrazeneca ab - anifrolumab - lupus erythematosus, sistemski - imunosupresivi - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.
seroquel sr 150 mg tablete s podaljšanim sproščanjem
astrazeneca ab - kvetiapin - tableta s podaljšanim sproščanjem - kvetiapin 150 mg / 1 tableta - kvetiapin
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukemija, dlakasta celica - antineoplastična sredstva - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
budfor 160 mikrogramov/4,5 mikrograma na odmerek, prašek za inhaliranje
astrazeneca ab - budezonid; formoterolijev fumarat dihidrat - prašek za inhaliranje - budezonid 160 µg / 1 odmerek formoterolijev fumarat dihidrat4,5 µg / 1 odmerek; formoterolijev fumarat dihidrat 4,5 µg / 1 odmerek - formoterol in budezonid
budfor 320 mikrogramov/9 mikrograma na odmerek, prašek za inhaliranje
astrazeneca ab - budezonid; formoterolijev fumarat dihidrat - prašek za inhaliranje - budezonid 320 µg / 1 odmerek formoterolijev fumarat dihidrat9 µg / 1 odmerek; formoterolijev fumarat dihidrat 9 µg / 1 odmerek - formoterol in budezonid
budfor 80 mikrogramov/4,5 mikrograma na odmerek, prašek za inhaliranje
astrazeneca ab - budezonid; formoterolijev fumarat dihidrat - prašek za inhaliranje - budezonid 80 µg / 1 odmerek formoterolijev fumarat dihidrat4,5 µg / 1 odmerek; formoterolijev fumarat dihidrat 4,5 µg / 1 odmerek - formoterol in budezonid